EVONILEEvonile Pharma Limited
Convert to ideaHealthcare · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeDown 6.0 this quarter.
Momentum from moving averages, Supertrend and RSI.
3 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
3 found · risk elevated
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹56 Cr | ₹-78 Cr | -63.71% | -138.34% | ₹-31.41 | -7.4x |
| Q1 FY2027 | ₹104 Cr | ₹32 Cr | 33.22% | 31.03% | ₹13.05 | Negligible |
| Q4 FY2026 | ₹91 Cr | ₹25 Cr | 22.31% | 27.89% | ₹10.23 | Negligible |
| Q3 FY2026 | ₹86 Cr | ₹16 Cr | 25.47% | 18.73% | ₹6.52 | 22.3x |
| Q2 FY2026 | ₹90 Cr | ₹24 Cr | 25.86% | 26.81% | ₹9.81 | Negligible |
| Q1 FY2026 | ₹88 Cr | ₹28 Cr | 30.51% | 31.55% | ₹11.19 | Negligible |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Novartis India Limited is involved in the pharmaceutical business in India. The company offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neuroscience products under the Tegrital and Exelon brands. Novartis India Limited was incorporated in 1947 and is headquartered in Mumbai, India. Novartis India Limited operates as a subsidiary of Novartis AG.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.